Ovid Therapeutics Inc (OVID) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting

Two preclinical studies to be presented on OV329, a potential next-generation GABA aminotransferase inhibitor...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results

A Phase 1 SAD/MAD study of OV329 is progressing as planned, and based on encouraging human safety data to date...

Ovid Therapeutics to Host Investor Event

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical...

Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin

Study found OV329 cleared and remained undetectable in the retina, eye, and brain tissues of mice, unlike...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical...

Ovid Therapeutics to Present at Upcoming September Investor Conferences

NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report